WO2022211303A1 - 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도 - Google Patents
3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도 Download PDFInfo
- Publication number
- WO2022211303A1 WO2022211303A1 PCT/KR2022/003384 KR2022003384W WO2022211303A1 WO 2022211303 A1 WO2022211303 A1 WO 2022211303A1 KR 2022003384 W KR2022003384 W KR 2022003384W WO 2022211303 A1 WO2022211303 A1 WO 2022211303A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- muscle
- compound
- formula
- treatment
- pharmaceutical composition
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract description 9
- 230000014509 gene expression Effects 0.000 claims abstract description 23
- 201000000585 muscular atrophy Diseases 0.000 claims abstract description 6
- 102100040669 F-box only protein 32 Human genes 0.000 claims abstract description 4
- 101710191029 F-box only protein 32 Proteins 0.000 claims abstract description 4
- 102000005604 Myosin Heavy Chains Human genes 0.000 claims description 24
- 108010084498 Myosin Heavy Chains Proteins 0.000 claims description 24
- 210000003205 muscle Anatomy 0.000 claims description 24
- 208000029578 Muscle disease Diseases 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 23
- 208000001076 sarcopenia Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 6
- 230000003287 optical effect Effects 0.000 claims description 5
- 206010028372 Muscular weakness Diseases 0.000 claims description 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 4
- 206010021118 Hypotonia Diseases 0.000 claims description 3
- 208000007379 Muscle Hypotonia Diseases 0.000 claims description 3
- 208000010428 Muscle Weakness Diseases 0.000 claims description 3
- 108010056785 Myogenin Proteins 0.000 claims description 3
- 206010061533 Myotonia Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 201000006938 muscular dystrophy Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 102000004364 Myogenin Human genes 0.000 claims 2
- 101001023028 Gallus gallus Myogenin Proteins 0.000 claims 1
- 230000008033 biological extinction Effects 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 101150094019 MYOG gene Proteins 0.000 abstract description 13
- 230000022379 skeletal muscle tissue development Effects 0.000 abstract description 7
- 230000006907 apoptotic process Effects 0.000 abstract description 6
- 230000001114 myogenic effect Effects 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 206010028289 Muscle atrophy Diseases 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000020763 muscle atrophy Effects 0.000 abstract description 3
- 210000000107 myocyte Anatomy 0.000 abstract description 2
- 229940126062 Compound A Drugs 0.000 description 27
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 24
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 18
- 230000008859 change Effects 0.000 description 10
- 230000003833 cell viability Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 6
- 101150017888 Bcl2 gene Proteins 0.000 description 6
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 description 6
- -1 alkaline earth metal salt Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 4
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 4
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003098 myoblast Anatomy 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 101710142060 Free fatty acid receptor 1 Proteins 0.000 description 2
- 229940125827 GPR40 agonist Drugs 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 102100032970 Myogenin Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 210000004262 dental pulp cavity Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
- 101000589002 Homo sapiens Myogenin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 150000008545 L-lysines Chemical class 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009511 drug repositioning Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000002660 insulin-secreting cell Anatomy 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009753 muscle formation Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- prevention means any action that inhibits or delays the onset of muscle loss-related diseases by administration of the composition.
- a pharmaceutically acceptable metal salt may be prepared using a base.
- the alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the compound in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and evaporating and drying the filtrate.
- it is pharmaceutically suitable to prepare a sodium, potassium or calcium salt as the metal salt.
- the corresponding salt is also obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (eg silver nitrate).
- the X-ray powder diffraction pattern has a diffraction peak at a value of 2 [ ⁇ ] selected from 4.61 ⁇ 0.2, 6.84 ⁇ 0.2, 11.74 ⁇ 0.2, 16.50 ⁇ 0.2, 16.94 ⁇ 0.2, 20.42 ⁇ 0.2, and 20.87 ⁇ 0.2. characterized.
- the crystalline form of the lysine salt of Formula 2 is characterized by being characterized by an X-ray powder diffraction pattern matching the peak positions listed in Table 1 below.
- the present inventors treated C2C12 cells, which are myoblasts, with the compound of Formula 1 to determine whether the compound of Formula 1 affects muscle loss or myogenesis. As a result, the expression of MyoG and MyHC, which are myogenic factors, increases, and myotube formation It was confirmed that this is promoted (Experimental Example 1).
- the compound of Formula 1 can inhibit muscle loss even in situations in which sarcopenia is accelerated, such as diabetes, obesity, and inflammatory reactions.
- sarcopenia is accelerated, such as diabetes, obesity, and inflammatory reactions.
- the Bax/Bcl2 ratio increases, the cell viability decreases, the expression of MyoG and MyHC also decreases, and the MyHC-positive area and the thickness of the myotube also decrease, resulting in muscle loss.
- palmitate and the compound of Formula 1 are treated together, the above phenomenon is reversed, which means that muscle loss is inhibited by the compound of Formula 1 (Experimental Example 2).
- the compound of Formula 1 exhibits an excellent effect of promoting myogenesis and inhibiting muscle loss. Accordingly, the present invention relates to the use of the compound of Formula 1, its optical isomer, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the prevention or treatment of muscle disease, as well as a pharmaceutical composition for the prevention or treatment of muscle disease, and Provided is a method for preventing or treating a muscle disease, comprising administering to a subject a therapeutically effective amount of a compound of Formula 1, an optical isomer, or a pharmaceutically acceptable salt thereof.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspension solutions, emulsions, lyophilized formulations, suppositories, and the like.
- Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
- injectable esters such as ethyl oleate.
- As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin, glycerol, gelatin, etc. may be used.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Caption | Angle | d value | Intensity | Intensity % |
2-Theta ° | Angstrom | Count | % | |
d=19.14506 | 4.612 | 19.14506 | 4735 | 89.4 |
d=16.07776 | 5.492 | 16.07776 | 2226 | 42 |
d=12.91070 | 6.841 | 12.9107 | 3738 | 70.6 |
d=7.53027 | 11.743 | 7.53027 | 5231 | 98.8 |
d=7.33717 | 12.053 | 7.33717 | 5296 | 100 |
d=6.44222 | 13.735 | 6.44222 | 4485 | 84.7 |
d=5.36804 | 16.501 | 5.36804 | 5215 | 98.5 |
d=5.22939 | 16.941 | 5.22939 | 4947 | 93.4 |
d=4.80573 | 18.447 | 4.80573 | 4289 | 81 |
d=4.64015 | 19.112 | 4.64015 | 4100 | 77.4 |
d=4.40719 | 20.132 | 4.40719 | 4188 | 79.1 |
d=4.34614 | 20.418 | 4.34614 | 4519 | 85.3 |
d=4.25406 | 20.865 | 4.25406 | 4692 | 88.6 |
d=4.11754 | 21.565 | 4.11754 | 3688 | 69.6 |
d=3.85747 | 23.038 | 3.85747 | 3021 | 57 |
d=3.55665 | 25.016 | 3.55665 | 2478 | 46.8 |
Claims (6)
- 화학식 1의 화합물, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 근육 질환의 예방 또는 치료용 약학적 조성물로서,상기 근육 질환은 근감소증(sarcopenia), 근위축증(muscular atrophy), 근무력증(myasthenia), 근이영양증(muscular dystrophy), 근육긴장증(myotonia), 근긴장 저하(hypotonia) 및 근력 약화(muscular weakness)로 이루어진 군에서 선택되는 하나 이상의 질환인, 근육 질환의 예방 또는 치료용 약학적 조성물.[화학식 1]
- 제1항에 있어서, 상기 화학식 1의 화합물은 근 생성 인자인 MyoG (myogenin) 또는 MyHC (myosin heavy chain)의 발현을 촉진하는, 근육 질환의 예방 또는 치료용 약학적 조성물.
- 제1항에 있어서, 상기 화학식 1의 화합물은 근 소멸 인자인 아트로진-1 (atrogin-1)의 발현을 감소시키는, 근육 질환의 예방 또는 치료용 약학적 조성물.
- 제4항에 있어서, 상기 화학식 2의 구조를 갖는 라이신염은 4.61 ± 0.2, 5.49 ± 0.2, 6.84 ± 0.2, 11.74 ± 0.2, 12.05 ± 0.2, 13.74 ± 0.2, 16.50± 0.2, 16.94 ± 0.2, 18.45 ± 0.2, 19.11 ± 0.2, 20.13 ± 0.2, 20.42 ± 0.2, 20.87 ± 0.2, 21.57 ± 0.2, 23.04 ± 0.2, 및 25.02 ± 0.2 로부터 선택되는 2[θ]값에서 4개 이상의 회절 피크를 가지는 X선 분말 회절 패턴으로 특정되는, 근육 질환의 예방 또는 치료용 약학적 조성물.
- 제1항 내지 제5항 중에서 어느 한 항에 따른 근육 질환의 예방 또는 치료용 약학적 조성물을 치료가 필요한 개체에 투여하는 투여하는 단계를 포함하는 근육 질환의 치료 방법으로서,상기 근육 질환은 근감소증, 근위축증, 근무력증, 근이영양증, 근육긴장증, 근긴장 저하 및 근력 약화로 이루어진 군에서 선택되는 하나 이상의 질환인, 근육 질환의 치료 방법.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22781424.1A EP4316486A1 (en) | 2021-04-01 | 2022-03-10 | Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative |
JP2023560714A JP2024512744A (ja) | 2021-04-01 | 2022-03-10 | 3-(4-(ベンジルオキシ)フェニル)ヘキサ-4-イン酸誘導体の新規用途 |
CN202280032110.9A CN117241793A (zh) | 2021-04-01 | 2022-03-10 | 3-(4-(苄氧基)苯基)己-4-炔酸衍生物的新用途 |
MX2023011661A MX2023011661A (es) | 2021-04-01 | 2022-03-10 | Uso novedoso del derivado de acido 3-(4-(benciloxi)fenil)hex-4-ino ico. |
BR112023019664A BR112023019664A2 (pt) | 2021-04-01 | 2022-03-10 | Composição farmacêutica para prevenir ou tratar doenças musculares, e, método para tratar doenças musculares |
AU2022247120A AU2022247120A1 (en) | 2021-04-01 | 2022-03-10 | Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative |
CA3213380A CA3213380A1 (en) | 2021-04-01 | 2022-03-10 | Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative |
US18/552,988 US20240197674A1 (en) | 2021-04-01 | 2022-03-10 | Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210042939A KR20220136800A (ko) | 2021-04-01 | 2021-04-01 | 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도 |
KR10-2021-0042939 | 2021-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022211303A1 true WO2022211303A1 (ko) | 2022-10-06 |
Family
ID=83457655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/003384 WO2022211303A1 (ko) | 2021-04-01 | 2022-03-10 | 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20240197674A1 (ko) |
EP (1) | EP4316486A1 (ko) |
JP (1) | JP2024512744A (ko) |
KR (1) | KR20220136800A (ko) |
CN (1) | CN117241793A (ko) |
AU (1) | AU2022247120A1 (ko) |
BR (1) | BR112023019664A2 (ko) |
CA (1) | CA3213380A1 (ko) |
MX (1) | MX2023011661A (ko) |
WO (1) | WO2022211303A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130045990A1 (en) * | 2011-08-17 | 2013-02-21 | Eli Lilly And Company | Novel 1,2,3,4-tetrahydroquinoline derivative useful for the treatment of diabetes |
WO2014171762A1 (ko) * | 2013-04-18 | 2014-10-23 | 현대약품 주식회사 | 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
KR101666659B1 (ko) | 2014-06-12 | 2016-10-14 | 한국생명공학연구원 | 부틸 피리디늄 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물 |
WO2019108046A1 (ko) * | 2017-12-01 | 2019-06-06 | 현대약품 주식회사 | 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도 |
US20200039957A1 (en) * | 2017-03-31 | 2020-02-06 | Takeda Pharmaceutical Company Limited | Aromatic compound |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102150944B1 (ko) | 2018-04-17 | 2020-09-02 | 강릉원주대학교산학협력단 | 근력 강화 또는 근감소증 예방 및 치료용 조성물 |
-
2021
- 2021-04-01 KR KR1020210042939A patent/KR20220136800A/ko unknown
-
2022
- 2022-03-10 CA CA3213380A patent/CA3213380A1/en active Pending
- 2022-03-10 JP JP2023560714A patent/JP2024512744A/ja active Pending
- 2022-03-10 AU AU2022247120A patent/AU2022247120A1/en active Pending
- 2022-03-10 BR BR112023019664A patent/BR112023019664A2/pt unknown
- 2022-03-10 CN CN202280032110.9A patent/CN117241793A/zh active Pending
- 2022-03-10 US US18/552,988 patent/US20240197674A1/en active Pending
- 2022-03-10 WO PCT/KR2022/003384 patent/WO2022211303A1/ko active Application Filing
- 2022-03-10 EP EP22781424.1A patent/EP4316486A1/en active Pending
- 2022-03-10 MX MX2023011661A patent/MX2023011661A/es unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130045990A1 (en) * | 2011-08-17 | 2013-02-21 | Eli Lilly And Company | Novel 1,2,3,4-tetrahydroquinoline derivative useful for the treatment of diabetes |
WO2014171762A1 (ko) * | 2013-04-18 | 2014-10-23 | 현대약품 주식회사 | 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
KR101666659B1 (ko) | 2014-06-12 | 2016-10-14 | 한국생명공학연구원 | 부틸 피리디늄 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물 |
US20200039957A1 (en) * | 2017-03-31 | 2020-02-06 | Takeda Pharmaceutical Company Limited | Aromatic compound |
WO2019108046A1 (ko) * | 2017-12-01 | 2019-06-06 | 현대약품 주식회사 | 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도 |
Non-Patent Citations (1)
Title |
---|
HAMDOUCHI CHAFIQ, KAHL STEVEN D., PATEL LEWIS ANJANA, CARDONA GUEMALLI R., ZINK RICHARD W., CHEN KEYUE, EESSALU THOMAS E., FICORIL: "The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 59, no. 24, 22 December 2016 (2016-12-22), US , pages 10891 - 10916, XP055972684, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.6b00892 * |
Also Published As
Publication number | Publication date |
---|---|
MX2023011661A (es) | 2023-10-11 |
EP4316486A1 (en) | 2024-02-07 |
CA3213380A1 (en) | 2022-10-06 |
KR20220136800A (ko) | 2022-10-11 |
BR112023019664A2 (pt) | 2024-01-16 |
AU2022247120A1 (en) | 2023-10-26 |
CN117241793A (zh) | 2023-12-15 |
US20240197674A1 (en) | 2024-06-20 |
JP2024512744A (ja) | 2024-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101524165B1 (ko) | Hiv 인테그라제 억제제의 약동학을 개선하기 위한 방법 | |
KR0153532B1 (ko) | 상피소체 기능 항진증 치료용 약제 조성물 | |
US20070197602A1 (en) | Combined pharmaceutical composition | |
WO2011002001A1 (ja) | ピラゾール誘導体とビグアナイド薬との組み合わせ医薬 | |
JP4814789B2 (ja) | 6−ヒドロキシベンズブロマロン又はその塩からなる医薬組成物 | |
CS208661B2 (en) | Method of making the n-/2-phenyl-2-hydroxyethyl/-1,1-dimethyl-3-phenylpropylamin derivatives | |
WO2022055285A1 (ko) | 암의 기원 세포의 사멸용 약학적 조성물 | |
WO2022057906A1 (zh) | 一种用于防治肝病的化合物及其制药用途 | |
US6399658B1 (en) | Composition containing ascorbic acid | |
WO2022211303A1 (ko) | 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도 | |
KR20230079163A (ko) | 티아다이아졸론 유도체와 당뇨병 및 관련 장애를 치료하기 위한 ampk 작용제로서 그 용도 | |
WO2018155921A1 (ko) | 고시폴 및 펜포르민을 유효성분으로 포함하는 췌장암 예방 및 치료용 약학적 조성물 | |
EP0838220A1 (en) | Drug for ameliorating brain diseases | |
US20230218563A1 (en) | Methods for treating or preventing chronic kidney disease | |
CN114929682A (zh) | 苯并硫代吡喃酮类化合物的盐及其制备方法和用途 | |
WO2022139487A1 (ko) | 신규한 펩타이드 및 이의 용도 | |
WO2024136627A1 (ko) | 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 비알코올성 지방간 질환 예방 또는 치료용 약학적 조성물 | |
WO2024085624A1 (ko) | 항비만 효능이 있는 호염성 바실러스 벨레젠시스 kmu01 균주 발효 배양상등액의 마이크로바이옴 조성물 | |
WO2024072079A1 (ko) | 이나보글리플로진을 포함하는 심혈관 노화 질환 예방 또는 치료용 약학 조성물 | |
EP0274230B1 (en) | Use of 2-oxo-imidazolidine derivatives in the prophylaxis and treatment of heart failure | |
US7001896B2 (en) | Compositions for treating diabetes | |
US4562071A (en) | Method of treating diabetic nephropathy | |
CN116648445A (zh) | 治疗或预防慢性肾脏病的方法 | |
CN114601827A (zh) | GN44028在治疗SARS-CoV-2感染中的应用 | |
JP2003095949A (ja) | 糖取り込み促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22781424 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3213380 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18552988 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/011661 Country of ref document: MX Ref document number: 2023560714 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023019664 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022247120 Country of ref document: AU Ref document number: 2022247120 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2022247120 Country of ref document: AU Date of ref document: 20220310 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280032110.9 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023124980 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022781424 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022781424 Country of ref document: EP Effective date: 20231102 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112023019664 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230925 |